{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:24:25Z","timestamp":1791469465023,"version":"4.3.4"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Methadone treatment is the most effective evidence-based treatment for opioid use disorder (OUD), but challenges related to dosing and premature treatment dropout argue for adjunct interventions to improve outcomes. One potential behavioral intervention with low risk involves harnessing placebo effects.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the effect of a pharmacologically conditioned open-label placebo (C-OLP) on 90-day methadone dose, retention, drug use, withdrawal, craving, quality of life, and sleep.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This 2-arm, open-label, single-blind randomized clinical trial was conducted between December 5, 2017, and August 2, 2019, in an academically affiliated community opioid treatment program. Analyses were conducted between October 1, 2019, and April 30, 2020. A total of 320 newly enrolled adults seeking treatment for moderate to severe OUD were assessed for study eligibility; 131 met eligibility criteria, provided informed consent, and were randomized to either C-OLP or treatment as usual (TAU) in an unequal-block (3:2) manner. Exclusion criteria were pregnancy, hospital\/program transfers, and court-ordered treatment.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants randomized to C-OLP received pharmacologic conditioning and a placebo pill and methadone, and participants randomized to TAU were given methadone only. Participants met with the study team 5 times: at baseline (treatment intake) and 2, 4, 8, and 12 weeks postbaseline. Interactions were balanced between the 2 groups.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes included 90-day methadone dose (primary) and treatment retention, drug use, withdrawal, craving, quality of life, and sleep quality (secondary). Analyses were conducted as intention-to-treat.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 131 people enrolled in the study, 54 were randomized to TAU and 77 to C-OLP. Mean (SD) age was 45.9 (11.2) years; most of the participants were Black or African American (83 [63.4%]) and male (84 [64.1%]). No significant group differences were observed in the mean (SD) 90-day methadone dose (83.1 [25.1] mg for group TAU, 79.4 [19.6] mg for group C-OLP;\n t<\/jats:italic>\n \u2009=\u20090.6219\n 91<\/jats:sub>\n ;\n P<\/jats:italic>\n \u2009=\u2009.43), but the groups differed significantly in their retention rates: 33 (61.1%) for TAU and 60 (77.9%) for C-OLP (\u03c7\n 2<\/jats:sup>\n 1<\/jats:sub>\n \u2009=\u20094.356;\n P<\/jats:italic>\n \u2009=\u2009.04; number needed to treat for the beneficial outcome of 3-month treatment retention, 6; 95% CI, 4-119). C-OLP participants also reported significantly better sleep quality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, C-OLP had no effect on the primary outcome of 90-day methadone dose. However, C-OLP participants were significantly more likely to remain in treatment. These findings support the use of C-OLP as a methadone treatment adjunct, but larger trials are needed to further examine the use of C-OLP.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02941809<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.7099","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:04:26Z","timestamp":1681297466000},"page":"e237099","source":"Crossref","is-referenced-by-count":18,"title":["Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Annabelle M.","family":"Belcher","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebonie","family":"Massey","sequence":"additional","affiliation":[{"name":"Center for Substance Abuse Research, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Billing","sequence":"additional","affiliation":[{"name":"Center for Substance Abuse Research, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[{"name":"Center for Substance Abuse Research, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wooten","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Hoag","sequence":"additional","affiliation":[{"name":"Applied Pharmaceutics Lab, University of Maryland School of Pharmacy, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson M.","family":"Wickwire","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"},{"name":"Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Greenblatt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Colloca","sequence":"additional","affiliation":[{"name":"Pain and Translational Symptom Science, University of Maryland School of Nursing, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Magder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Wish","sequence":"additional","affiliation":[{"name":"Center for Substance Abuse Research, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted J.","family":"Kaptchuk","sequence":"additional","affiliation":[{"name":"Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"22","key":"zoi230235r1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi230235r2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride.","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"issue":"3","key":"zoi230235r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi230235r4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"zoi230235r5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10550887.2011.610710","article-title":"QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.","volume":"30","author":"Martin","year":"2011","journal-title":"J Addict Dis"},{"issue":"1","key":"zoi230235r6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJMp1504023","article-title":"Placebo effects in medicine.","volume":"373","author":"Kaptchuk","year":"2015","journal-title":"N Engl J Med"},{"issue":"Pt B","key":"zoi230235r7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pnpbp.2017.06.003","article-title":"Role of placebo effects in pain and neuropsychiatric disorders.","volume":"87","author":"Belcher","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"zoi230235r8","doi-asserted-by":"publisher","first-page":"m1668","DOI":"10.1136\/bmj.m1668","article-title":"Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice.","volume":"370","author":"Kaptchuk","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"zoi230235r9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/j.pain.0000000000001390","article-title":"The IASP classification of chronic pain for ICD-11: chronic primary pain.","volume":"160","author":"Nicholas","year":"2019","journal-title":"Pain"},{"issue":"2","key":"zoi230235r10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jebm.2017.10.issue-2","article-title":"Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis.","volume":"10","author":"Charlesworth","year":"2017","journal-title":"J Evid Based Med"},{"issue":"1","key":"zoi230235r11","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1038\/s41598-021-83148-6","article-title":"Effects of open-label placebos in clinical trials: a systematic review and meta-analysis.","volume":"11","author":"von Wernsdorff","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"zoi230235r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015591","article-title":"Placebos without deception: a randomized controlled trial in irritable bowel syndrome.","volume":"5","author":"Kaptchuk","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"zoi230235r13","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1097\/j.pain.0000000000002234","article-title":"Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.","volume":"162","author":"Lembo","year":"2021","journal-title":"Pain"},{"issue":"4","key":"zoi230235r14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapediatrics.2021.5750","article-title":"Effect of open-label placebo on children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized clinical trial.","volume":"176","author":"Nurko","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"12","key":"zoi230235r15","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1097\/j.pain.0000000000000700","article-title":"Open-label placebo treatment in chronic low back pain: a randomized controlled trial.","volume":"157","author":"Carvalho","year":"2016","journal-title":"Pain"},{"key":"zoi230235r16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.853497","article-title":"Open-label placebo administration decreases pain in elderly patients with symptomatic knee osteoarthritis - a randomized controlled trial.","volume":"13","author":"Olliges","year":"2022","journal-title":"Front Psychiatry"},{"issue":"12","key":"zoi230235r17","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1097\/j.pain.0000000000001683","article-title":"Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial.","volume":"160","author":"Kleine-Borgmann","year":"2019","journal-title":"Pain"},{"issue":"5","key":"zoi230235r18","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/j.pain.0000000000002162","article-title":"Open-label placebo for chronic low back pain: a 5-year follow-up.","volume":"162","author":"Carvalho","year":"2021","journal-title":"Pain"},{"issue":"6","key":"zoi230235r19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000447242","article-title":"Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial.","volume":"85","author":"Schaefer","year":"2016","journal-title":"Psychother Psychosom"},{"issue":"3","key":"zoi230235r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192758","article-title":"Why do open-label placebos work? a randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis.","volume":"13","author":"Schaefer","year":"2018","journal-title":"PLoS One"},{"issue":"218","key":"zoi230235r21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006175","article-title":"Altered placebo and drug labeling changes the outcome of episodic migraine attacks.","volume":"6","author":"Kam-Hansen","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"zoi230235r22","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00520-018-4477-6","article-title":"Open-label placebo reduces fatigue in cancer survivors: a randomized trial.","volume":"27","author":"Zhou","year":"2019","journal-title":"Support Care Cancer"},{"issue":"1","key":"zoi230235r23","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1038\/s41598-018-20993-y","article-title":"Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial.","volume":"8","author":"Hoenemeyer","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"zoi230235r24","doi-asserted-by":"publisher","first-page":"20090","DOI":"10.1038\/s41598-020-77255-z","article-title":"Open-label placebos for menopausal hot flushes: a randomized controlled trial.","volume":"10","author":"Pan","year":"2020","journal-title":"Sci Rep"},{"key":"zoi230235r25","doi-asserted-by":"publisher","first-page":"k3889","DOI":"10.1136\/bmj.k3889","article-title":"Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?","volume":"363","author":"Kaptchuk","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi230235r26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1523\/JNEUROSCI.19-01-00484.1999","article-title":"Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems.","volume":"19","author":"Amanzio","year":"1999","journal-title":"J Neurosci"},{"issue":"10","key":"zoi230235r27","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1523\/JNEUROSCI.23-10-04315.2003","article-title":"Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo\/nocebo responses.","volume":"23","author":"Benedetti","year":"2003","journal-title":"J Neurosci"},{"issue":"8","key":"zoi230235r28","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/j.pain.0000000000000566","article-title":"Relieving pain using dose-extending placebos: a scoping review.","volume":"157","author":"Colloca","year":"2016","journal-title":"Pain"},{"issue":"3","key":"zoi230235r29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5214\/ans.0972-7531","article-title":"Conditioned reflexes: an investigation of the physiological activity of the cerebral cortex.","volume":"17","author":"Pavlov","year":"2010","journal-title":"Ann Neurosci"},{"issue":"3541","key":"zoi230235r30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1126\/science.138.3541.677","article-title":"Placebo effect in the rat.","volume":"138","author":"Herrnstein","year":"1962","journal-title":"Science"},{"issue":"2","key":"zoi230235r31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00006842-197403000-00011","article-title":"Letter: Behaviorially conditioned immunosuppression.","volume":"36","author":"Ader","year":"1974","journal-title":"Psychosom Med"},{"issue":"3-4","key":"zoi230235r32","first-page":"263","article-title":"Conditioning of the immune response.","volume":"39","author":"Ader","year":"1991","journal-title":"Neth J Med"},{"issue":"1","key":"zoi230235r33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/cch.2008.34.issue-1","article-title":"Open-label use of placebos in the treatment of ADHD: a pilot study.","volume":"34","author":"Sandler","year":"2008","journal-title":"Child Care Health Dev"},{"issue":"5","key":"zoi230235r34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/DBP.0b013e3181e121ed","article-title":"Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?","volume":"31","author":"Sandler","year":"2010","journal-title":"J Dev Behav Pediatr JDBP"},{"issue":"6","key":"zoi230235r35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000503038","article-title":"Are conditioned open placebos feasible as an adjunctive treatment to opioids? results from a single-group dose-extender pilot study with acute pain patients.","volume":"88","author":"Bernstein","year":"2019","journal-title":"Psychother Psychosom"},{"issue":"4","key":"zoi230235r36","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000828","article-title":"Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control.","volume":"5","author":"Morales-Quezada","year":"2020","journal-title":"Pain Rep"},{"issue":"6","key":"zoi230235r37","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1097\/j.pain.0000000000002185","article-title":"Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial.","volume":"162","author":"Flowers","year":"2021","journal-title":"Pain"},{"issue":"2","key":"zoi230235r38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/PSY.0b013e3181cbd38b","article-title":"Conditioned pharmacotherapeutic effects: a preliminary study.","volume":"72","author":"Ader","year":"2010","journal-title":"Psychosom Med"},{"issue":"9","key":"zoi230235r39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.sleep.2015.06.015","article-title":"Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study.","volume":"16","author":"Perlis","year":"2015","journal-title":"Sleep Med"},{"issue":"4","key":"zoi230235r40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000126074","article-title":"Behavioral conditioning of antihistamine effects in patients with allergic rhinitis.","volume":"77","author":"Goebel","year":"2008","journal-title":"Psychother Psychosom"},{"issue":"16","key":"zoi230235r41","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1073\/pnas.1720548115","article-title":"Learned immunosuppressive placebo responses in renal transplant patients.","volume":"115","author":"Kirchhof","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"zoi230235r42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026604","article-title":"Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.","volume":"9","author":"Belcher","year":"2019","journal-title":"BMJ Open"},{"key":"zoi230235r43","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"zoi230235r46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.pain.2010.08.007","article-title":"How the number of learning trials affects placebo and nocebo responses.","volume":"151","author":"Colloca","year":"2010","journal-title":"Pain"},{"issue":"8","key":"zoi230235r48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/archpsyc.1981.01780330033003","article-title":"Treatment for drug abuse: follow-up outcomes and length of time spent.","volume":"38","author":"Simpson","year":"1981","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"zoi230235r49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0376-8716(96)01230-6","article-title":"Retention in a low-threshold methadone maintenance program.","volume":"41","author":"Torrens","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi230235r50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal.","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"zoi230235r51","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1037\/a0012686","article-title":"Effects of a context shift and multiple context extinction on reactivity to alcohol cues.","volume":"16","author":"MacKillop","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"issue":"6","key":"zoi230235r52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/ADM.0000000000000169","article-title":"Effects of prereactivation propranolol on cocaine craving elicited by imagery script\/cue sets in opioid-dependent polydrug users: a randomized study.","volume":"9","author":"Jobes","year":"2015","journal-title":"J Addict Med"},{"issue":"3","key":"zoi230235r53","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF quality of life assessment.","volume":"28","author":"The WHOQOL Group","year":"1998","journal-title":"Psychol Med"},{"issue":"2","key":"zoi230235r54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"2","key":"zoi230235r55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi230235r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103813","article-title":"Peer recovery specialist-delivered, behavioral activation intervention to improve retention in methadone treatment: results from an open-label, type 1 hybrid effectiveness-implementation pilot trial.","volume":"108","author":"Magidson","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi230235r57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.imr.2019.08.002","article-title":"Acupuncture using pattern-identification for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials.","volume":"8","author":"Kim","year":"2019","journal-title":"Integr Med Res"},{"key":"zoi230235r58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctim.2016.02.007","article-title":"A systematic review of acupuncture for sleep quality in people with insomnia.","volume":"26","author":"Shergis","year":"2016","journal-title":"Complement Ther Med"},{"key":"zoi230235r59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.addbeh.2017.07.016","article-title":"Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.","volume":"76","author":"Dunn","year":"2018","journal-title":"Addict Behav"},{"issue":"4","key":"zoi230235r60","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11325-020-02123-z","article-title":"Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment.","volume":"24","author":"Baldassarri","year":"2020","journal-title":"Sleep Breath"},{"issue":"4","key":"zoi230235r61","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.v29.4","article-title":"Dynamic features of placebo effects addressing persistent insomnia disorder: a meta-analysis of placebo-controlled randomized clinical trials.","volume":"29","author":"Jiang","year":"2020","journal-title":"J Sleep Res"},{"key":"zoi230235r44","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi230235r45","unstructured":"CBS New York. Seen at 11: prescription placebo. CBS New York. 2016. Accessed March 14, 2019. https:\/\/www.youtube.com\/watch?v=Jp14Lhl0T9w"},{"key":"zoi230235r47","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). TIP 63: medications for opioid use disorder. 2021. Accessed March 7, 2023. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803739\/belcher_2023_oi_230235_1680705734.4243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:04:34Z","timestamp":1681297474000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803739"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7099","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}